Prs Reit (The) PLC ORD 1P/ GB00BF01NH51 /
31/05/2024 21:00:00 | Diferencia -0.9000 | Volumen | Bid31/05/2024 | Ask31/05/2024 | Máximo del día | Price Change Band |
---|---|---|---|---|---|---|
76.9000GBX | -1.16% | 468,254 Volumen de negocios(GBP): 360,248.2550 |
-Volumen de oferta: - | 94.5000Tamaño/ Volumen/ Formato de Ask: 6,000 | 77.8000 | 76.9000 |
GlobeNewswire
19:02
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pret...
GlobeNewswire
16:00
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstr...
GlobeNewswire
16:00
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Gli...
GlobeNewswire
16:00
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire
15:14
Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
GlobeNewswire
15:00
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Ther...
GlobeNewswire
15:00
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monothera...
GlobeNewswire
14:15
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with ...
GlobeNewswire
14:15
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
GlobeNewswire
14:05
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
GlobeNewswire
14:00
Kaskela Law LLC Announces Shareholder Investigation of WideOpenWest, Inc. (NYSE: WOW) and Encourages...
GlobeNewswire
14:00
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonst...
GlobeNewswire
14:00
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin)...
GlobeNewswire
14:00
OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
GlobeNewswire
14:00
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at...
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página